- Home
- RCS vs NGNE Comparison
RCS vs NGNE Comparison
Compare RCS & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RCS | NGNE |
|---|---|---|
| Founded | 1994 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 284.6M | 327.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RCS | NGNE |
|---|---|---|
| Price | $5.78 | $18.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $40.14 |
| AVG Volume (30 Days) | 141.1K | ★ 152.7K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 10.12% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.51 | $6.88 |
| 52 Week High | $6.31 | $37.27 |
Technical Indicators
Market Signals| Indicator | RCS | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 33.42 | 47.33 |
| Support Level | $6.04 | $18.12 |
| Resistance Level | $6.15 | $20.44 |
| Average True Range (ATR) | 0.13 | 1.23 |
| MACD | -0.01 | 0.25 |
| Stochastic Oscillator | 5.45 | 56.93 |
Price Performance
Historical ComparisonAbout RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with the objective.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.